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Paksu- ja peräsuolen syöpä (CRC) on ruuansulatuskanavan yleisin syöpä. Sen esiasteita, adenoomia, on 
löydettävissä 30-40 %:lla länsimaisesta väestöstä. Adenoomista suurin osa ei kuitenkaan koskaan etene 
pahanlaatuisiksi. CRC:n arviontiin on käytössä lukuisia luokittelumenetelmiä. Kuitenkin uusia merkkiaineita 
tarvitaan potilaille sopivimpien hoitojen löytämiseksi. 
Alfa-hiilihappoanhydraasit (CA) ovat entsyymiperhe, jonka tärkein tehtävä on ylläpitää kehon happo-
emästasapainoa. Syöpäsoluissa nämä entsyymit pitävät solun sisäisen pH:n neutraalina happamoittaen 
samalla soluvälitilaa, mikä lisää kasvaimen kasvua ja auttaa kasvainsolujen tunkeutumisessa normaaliin 
kudokseen. 
 
Tutkimuksessamme selvitimme immunohistokemiallisesti neljän CA-isoentsyymmin esiintymistä CRC:stä 
otetuissa kudosnäytteissä ja esiintymisen mahdollista yhteyttä potilaiden ennusteeseen ja kasvainten 
kliinispatologisiin ominaisuuksiin. 
Tilastollisessa analyysissä merkitsevää korrelaatio vaarasuhteessa havaittiin CA II ja CA XII entsyymien 
värjäytyvyyden voimakkuudessa ja CA II:n levinneisyydessä. Vastaavaa ei havaittu CA VII ja CA IX 
entsyymeillä, eikä CA XII:n levinneisyydessä.  
Löydöstemme perusteella CA II:n ja CA XII:n esiintyvyydellä voi olla merkitystä paksu- ja peräsuolen syövän 
kehittymisessä. Niiden käyttöä diagnostiikassa olisi syytä tutkia jatkossa enemmän. 
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Abstract 
 
Background, Colorectal adenocarcinoma is the most common cancer of the gastrointestinal tract. 
It usually develops from precursory adenomas, most of which are benign and do not proceed to 
cancer. Histopathological diagnostics of colorectal cancer is still based on tumor staging and 
grading, and unfortunately, there are very few biomarkers which provide useful information for 
assessment of the most suitable treatment in each case. Alpha-carbonic anhydrases (CAs) play an 
important role in maintaining acid-base homeostasis of the body. Importantly, several cancer 
types overexpress some CA isozymes, most remarkably the transmembrane isoforms CA IX and CA 
XII. These enzymes maintain intracellular pH within normal limits and simultaneously contribute to 
acidification of tumor microenvironment, which in turn, promotes tumor growth and malignant 
cell invasion; Methods, In this study, we defined expression of four CA isozymes, CA II, CA VII, CA 
IX, and CA XII, in colon carcinomas to find if there is any correlation between the enzyme 
expression levels and survival rate of patients. We also analyzed possible correlations to some 
important clinicopathological parameters, such as cell proliferation, tumor grade and stage; 
Results, Our results showed significant changes in hazard ratios, correlating to CA II and CA XII 
intensities. No correlations were found between CA VII or CA IX immunostaining results and the 
other parameters; Conclusions, The present findings indicate that CA II and CA XII could have 
some role as predictive factors in the diagnostics of colorectal cancer. Even though the significant 
findings were only associated to the staining intensity, this research line deserves further 
investigations because of the shortage of suitable biomarkers in clinical cancer diagnostics.  
Keywords: biomarker, carbonic anhydrase, colorectal cancer, immunohistochemistry, prognosis, 
survival 
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Background 
Colorectal cancer is the most common malignant disease of the gastrointestinal (GI) tract, and it is 
the second most common cancer in women and third in men [1]. Its incidence rate shows high 
regional variation, resulting in a 10-fold difference between countries [1]. The number of patients 
with colorectal cancer and precancerous lesions or polyps is increasing, which causes significant 
challenges to national healthcare systems and their possibilities to recognize early enough 
different tumor types to apply the most effective treatment. According to recent data the 
incidence of colorectal cancer is rising in many historically low-incidence countries like Japan, 
Korea, China and Eastern Europe, which is thought to be a result of cultural and dietary changes 
associated with Western lifestyle [1]. Even though the overall incidence is increasing, there has 
been some positive development in many previous high-risk countries at the same time. This is 
thought to be mainly because of more effective diagnostics and treatment.  
Colorectal adenocarcinoma usually develops from benign precursor lesions i.e. colonic adenomas 
[2]. Prevalence of adenomas clearly increases by age. Postmortem studies have indicated that 30-
40 % of individuals from Western countries have adenomas and most of them are asymptomatic 
[3]. Majority of these are benign and do not transform to malignant adenocarcinomas [2]. There 
are also familial syndromes where younger patients develop these adenomas, which proceed to 
cancer with a much higher percentage [2-4]. Precancerous lesions are often removed during 
colonoscopy, which prevents them to proceed to cancer, and thus, an early diagnostics combined 
with a complete tumor removal are the key factors for the most successful outcome.  
The diagnostic armamentarium of colorectal cancer includes several clinicopathological 
parameters, which can be utilized to determine the malignancy and prognosis of each case. They 
include TNM (tumor, nodes, metastasis), Dukes or Astler-Coller staging, tumor grade, 
microsatellite instability, and some molecular markers which have been recently reviewed by 
Marzouk and Schofield [5]. Earlier some other molecular markers, such as tumor suppressor gene 
p53 and its mutations as well as antigen Ki-67, have also been associated with tumor proliferation 
and cancer prognosis [6, 7]. However, new biomarkers are urgently needed to improve the 
stratification of colorectal cancer patients for different treatment options.  
Carbonic anhydrases (CAs) constitute a group of zinc-binding enzymes which catalyze the 
reversible hydration of CO2 to bicarbonate. This reaction is crucial for maintenance of pH 
homeostasis of the body. Through this chemical reaction they are involved in several downstream 
physiological processes, such as bone resorption, vision, and production of saliva, bile, pancreatic 
juice and gastric juice [8-10]. The mammalian alpha-CA family includes 16 known isoforms of 
which 15 can be found in humans. These isoforms show marked differences in their kinetics and 
cellular and subcellular distributions [8, 9]. Although the functions of CA enzymes in cancer cells 
have been extensively studied, their exact roles are still incompletely understood.  
CA proteins have been studied extensively during the last 20 years as potential markers for various 
cancers. Cytosolic CA II is the most widely expressed isozyme in normal tissues, such as gastric, 
pancreatic, biliary, and intestinal epithelia [10, 14]. It is often absent or only weakly expressed in 
malignant tumors. Recently, CA II was shown to be highly overexpressed in gastrointestinal 
stromal tumors and was suggested as a potential biomarker for this mesenchymal tumor type 
[15]. CA VII is another cytosolic isozyme which shows a more restricted tissue distribution than CA 
II. It is predominantly expressed in the brain where it contributes to bicarbonate-driven GABAergic 
excitation [16]. A recent study showed that CA VII is overexpressed in glioblastomas, suggesting 
that it may represent another tumor-associated CA isoform [17].  
CA IX has attracted lots of attention, because its expression is limited to few normal tissues, such 
as gastric, intestinal and gall bladder epithelia, and it is highly overexpressed in hypoxic tumors 
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[10-12]. CA XII is another isoform which is overexpressed in several cancers, even though it is also 
present in various normal tissues. It has been demonstrated in both the normal intestinal 
epithelium and malignant colorectal tumors [10, 12, 13]. CA IX and XII, are known to be regulated 
via von Hippel Lindau (vHL) / hypoxia inducible factor (HIF) pathway [18].  
Under hypoxic conditions cells produce acidic metabolic products via anaerobic glycolysis. This 
pathway is inhibited in the presence of enough oxygen. Notably, tumor cells have a tendency to 
upregulate glucose intake and increase the rate of anaerobic glycolysis even if the amount of 
oxygen is sufficient [19]. Tumor cells need CA enzymes among many other proteins, such as ion 
transporters, to maintain the neutral intracellular pH [20]. During this process extracellular pH 
decreases, which in turn, disturbs physiological processes of the surrounding normal tissue and 
promotes cancer growth [19, 21]. Indeed, increased glucose intake and hypoxia are often signs of 
more aggressive and invasive tumors, which also correlate with a poor prognosis [19]. It has been 
suggested that partial hypoxia may contribute to cell selection, favoring a shift from a pre-
malignant phenotype to more malignant forms where the oxygen free metabolism plays a major 
role and the cells can survive in challenging hypoxic environments [19]. 
The aim of this research is to investigate the expression of isozymes CA II, CA VII, CA IX, and CA XII 
in colon carcinomas. The expression levels of these enzymes assessed by immunohistochemistry 
are correlated to the data obtained from clinical and pathological analyses. Our results show that 
both CA II and CA XII staining intensities correlate with the survival rate of colorectal cancer 
patients, suggesting a potential role for these enzymes as prognostic biomarkers.  
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Methods 
Overall 840 patients with colorectal carcinoma were operated in Helsinki University hospital 
during years 1983-2001 and the specimens and clinical data from 645 patients were available for 
our study. The ethical committee of the University Hospital (Dnro 226/E6/06) and National 
Supervisory Authority for Welfare and Health (Dnro 3990/04/046/07) had granted permission for 
the use of these samples. Survival data were available for all patients and obtained from patient 
records, the Finnish Cancer Registry and Statistics Finland. The clinicopathological characteristics 
of the patients are described in detail in table 1. 
Tumor samples were arranged as multitissue arrays. Of 645 patient samples we obtained, 106 
ended up with no scoring results. This was mainly because these samples were either washed out 
or displaced during the staining process. 539 samples were considered representative enough to 
be graded and analyzed. The microscope slides containing the tissue specimens were 
immunostained with rabbit anti-human CA II, CA VII and CA XII sera or with monoclonal anti-
human CA IX antibody (M75). These antibodies have been previously utilized in numerous studies 
and have been shown to be specific for each isozyme [22-25]. Five µm sections were processed for 
immunoperoxidase staining, which was performed using an automated Lab Vision Autostainer 480 
(LabVision Corporation, Fremont, CA, USA). Automated immunostaining was performed using the 
Power Vision+ Poly-HRP Immunohistochemistry kit (ImmunoVision Technologies Co) reagents and 
included the following steps: (1) rinsing in wash buffer; (2) treatment in 3% H2O2 in ddH2O for five 
minutes and rinsing with wash buffer; (3) blocking with cow colostrum diluted 1:2 in Tris-buffered 
saline (TBS) containing 0.05% Tween-20 for 30 minutes and rinsing in wash buffer; (4) incubation 
with primary antibody (polyclonal antibodies diluted 1:2000 and monoclonal M75 diluted 1:100) 
for 30 minutes; (5) rinsing in wash buffer three times for five minutes; (6) incubation in poly-HRP-
conjugated anti-rabbit/mouse IgG for 30 minutes and rinsing in wash buffer three times for five 
minutes; (7) incubation in DAB (3,3`-diaminobenzidine tetrahydrochloride) solution (one drop of 
DAB solution A and one drop of DAB solution B in 1 ml of ddH2O) for six minutes and rinsing in 
ddH2O; (8) CuSO4 treatment for five minutes to enhance the signal and rinsing in ddH2O; (9) 
treatment with hematoxylin for one minute and (10) rinsing with ddH2O. All procedures were 
performed at room temperature. The mounting of the sections was performed using Entellan Neu 
(Merck; Darmstadt, Germany) and was finally examined and photographed with a Zeiss Axioskop 
40 microscope (Carl Zeiss; Göttingen, Germany). The intensity of the staining was scored on a scale 
of 0 to 3 as follows: 0, no reaction; 1, weak reaction; 2, moderate reaction; and 3, strong reaction. 
The extent of the staining was also scored as 1 when 1-10% of the cells stained, 2 when 11-50% of 
the cells stained and 3 when 51-100% of the cells stained. A negative score (0) was given to tissue 
sections that had no evidence of specific immunostaining. 
To get at least one representative scored value for each sample, two to three series of tissue array 
slides were stained for each isozyme. All unidentifiable samples and those which contained no 
tumor tissue were excluded from scoring. In addition to the analysis of tumor cells, CA II 
immunostaining was also evaluated in endothelial cells and CA VII in tumor stroma.  
 
Statistical analysis  
Results are announced as number of patients and percentage of patients, the Kaplan-Meier mean 
survival time with 95 % confidence intervals and the Cox regression hazard ratios and their 95 % 
confidence intervals (CI). p-values < 0.05 were considered statistically significant. Two-tailed tests 
were used. 
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The Kaplan-Meier analysis and the Cox regression hazard ratio model were used to analyze the 
survival data. The assumption of constant hazard ratios over time was tested by including time 
dependent covariate for each testable variable. Because both Dukes classification and 
differentiation status did not follow the Cox model assumption, stratified analyses for Dukes class 
and differentiation were used. For statistical analyses, Dukes classifications A and B, as well as C 
and D were combined to reduce the number of groups to two. Same was done to tumor 
differentiation status, in which low and medium low differentiation were combined as well as 
medium high and high differentiation status. In the Cox proportional hazards model we included 
variables for age, sex and, side of the tumor. Separate analyses were made for each CA staining. 
In analysis male patients were compared to females and 65 years-old or older patients were 
compared to younger ones. Tumor location was also considered in the analysis: right side of the 
colon versus left side of the colon and rectum. 
When analyzing the expression of each CA enzyme, level 0 was considered the baseline and all 
other grading levels were compared to it. Announced hazard ratio rises exponentially every time 
when grading value rises one unit. Expression levels of CAs were also compared separately to the 
well-known tumor markers, p53 and Ki67. For statistical analysis p53 and Ki67 reactions were each 
divided into two groups (0-5 and >5).  
Statistical analyses were performed by SPSS v 10© (IBM corp, New York).  
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Results  
Four CA isozymes, CA II, VII, IX, and XII were selected for the immunohistochemical analysis of 
colorectal cancer. Summary of the immunohistochemical staining results is presented in table 2. 
Figure 1 demonstrates representative images of positive immunostaining of each isozyme in colon 
carcinoma specimens. Normal colon and pancreas specimens are shown as positive controls. Our 
main results, shown in figure 2, include Kaplan-Meier plots for the staining intensity and extent of 
each isozyme. In Kaplan-Meier analysis, there was a significant decreasing trend in survival as the 
intensity of CA II or CA XII, or the extent of CA II increased. The mean survival time decreased from 
17.7 years (95% CI, 14.8-20.6) to 12.3 years (95% CI, 10.5-14.2) as the CA II intensity increased 
from 0 to 3. The mean survival time decreased from 18.3 years (95% CI, 15.5-21.1) to 13.5 years 
(95% CI, 12.0-15.0) as the extent of CA II increased from 0 to 3. The mean survival time decreased 
from 16.5 years (95% CI, 13.7-19.2) to 9.9 years (95% CI, 7.3-12.4) as the intensity of CA XII 
increased from 0 to 3. In the Cox regression analysis, the most significant results were found for 
CA II staining intensity as shown in table 3. Increase in CA II intensity from 0 to 1 increased the age, 
sex, Dukes, differentiation and tumor side corrected hazard ratio to 1.19 fold (CI: 1.04-1.37 p = 
0.009). No significant interaction was, however, found between the CA II intensity and age, sex or 
location of tumor. When comparing the extent of the CA II staining to the survival rate, the result 
did not reach statistical significance. However, a significant interaction was found between the CA 
II staining extent and patients´ age, the hazard ratio being 1.59 fold (CI: 1.22-2.09, p = 0.001), 
suggesting that the CA II staining extent correlated better with survival in older patients. Notably, 
CA II-positive staining was often induced in the endothelium of tumor capillaries in addition to the 
actual tumor cells. In Kaplan-Meier analysis the vascular endothelial staining of CA II did not show 
any significant correlation to survival (p = 0.676). 
CA VII immunostaining results showed no significant correlation to patients´ survival which can be 
seen in figure 2. In the Kaplan-Meier survival analysis p-values were 0.566 for the staining intensity 
and 0.495 for the extent. Negative results were also observed for stromal staining (p=0.816 for 
intensity and p=0.591 for extent). There was a significant correlation (p=0.013) between the 
epithelial staining extent and Dukes classification. Over 50 % extent was found in Dukes classes 3 C 
and 4 D more frequently than expected, while it was more rarely found in classes 1 A and 2 B. 
These results are also shown in the table 4. The extent was 0 or under 10 % more frequently in 
class 4 D than expected. No significant correlation was found between the epithelial or stromal CA 
VII immunostaining and other parameters. 
In Kaplan-Meier analysis no significant correlation was found between the survival data and 
intensity (p = 0.879) or extent (p = 0.315) of CA IX immunostaining. Additionally, no correlation 
was found when the CA IX immunostaining results were compared with the other parameters. 
CA XII was another enzyme in this study, which showed a significant correlation when its staining 
intensity was compared to the survival data of colorectal cancer patients. In the Cox regression 
analysis increased intensity of CA XII immunostaining showed a slightly increased hazard ratio of 
1.18 (95% CI, 1.01-1.38, p=0.036, table 3). Gender or location of the tumor did not show any 
significant correlations. The extent of CA XII immunostaining showed no significant correlation to 
the patients´ survival in Kaplan-Meier analysis (p=0.242). Comparison of CA XII immunostaining 
results with the other clinicopathological parameters showed no significant correlations. 
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Discussion 
 
In our study, we found two isozymes, CA II and CA XII, which significantly correlated with the 
patients´ survival rate. Our results suggest that these proteins might have some value in the 
prognostic assessment of colorectal cancer patients when deciding which patients should undergo 
a more aggressive and demanding cancer treatment in order to curate or postpone cancer 
progression. On the other hand, enzyme expression can also define which patients have better 
prognosis and can be treated with less aggressive treatments. This can diminish side effects and 
increase life quality during treatments. Even though CA IX represents a promising biomarker for 
several cancers, our results suggested that it has no major role in histopathological diagnostics of 
colorectal carcinoma nor does it present any value as a prognostic factor in this tumor category.  
The role of different CA isozymes has been under intensive research during the last decade. These 
studies have been focused on the association between CA expression and tumor aggressiveness 
and patient survival, role in tumor metastasis as well as their possibility to act as potential targets 
to anticancer drugs [21, 26-28]. CA isozymes have shown abnormal expression in various 
malignant tumors compared to normal cells and tissues [17, 19, 21, 28-30]. In one of the early 
studies, CA IX was shown to be diffusely expressed in colorectal cancer, whereas the normal or 
adenomatous mucosa showed a more limited distribution [11]. Immunostaining of serial sections 
for Ki-67 confirmed that CA IX was expressed in areas with high proliferative capacity. Similarly, CA 
XII showed a more diffuse immunostaining reaction in colorectal carcinomas compared to the 
normal colon or adenomas [13]. Cytosolic CA II isozyme has shown a very different distribution. It 
is highly expressed in several normal gastrointestinal tract tissues, such as gastric and intestinal 
mucosa [14], but is clearly downregulated in most colorectal tumors [31]. The same phenomenon 
may also occur in the case of the other cytosolic CAs [32]. CA VII expression was found to be 4-fold 
downregulated in sigmoid or rectosigmoid carcinomas compared to the normal tissue according to 
Birkenkamp-Demtroder´s study [33]. Recently, Niemelä et al. [34] reported cDNA microarray 
results on the expression of all CAs, except for CA XIII, in both normal and malignant colorectal 
specimens. The fold-changes for our target CA isozymes were: CA II (-7.4 (normal mucosa vs. 
sporadic carcinoma)), CA VII (-4.3), CA IX (+2.4) and CA XII (-3.2). In our figure 1 the increase of 
expression is clearly demonstrated in the case of CA IX, whereas the interpretation is more difficult 
with the other isozymes because of high staining intensities in both the normal and tumor tissues. 
Even though the pathogenesis of colorectal cancer has been intensively studied during the last 
decades, there are still molecular mechanisms that clearly warrant more research. For example, it 
was recently shown that polyps with any advanced neoplastic features are smaller in the right side 
than in the left side of the colon, and the gene expression is also different from side to side [33, 
35]. In our study, we analyzed the possible correlation between the enzyme expression and the 
side of the colon. According to this analysis, the reactivity of CA enzymes showed no correlation to 
the tumor location. The main clinicopathological factors affecting colorectal cancer patients’ 
survival are the tumor grade, resection margins in the operation, and the presence or absence of 
lymph node metastases [3]. Other factors with prognostic significance include tumor budding, 
micrometastases, peritoneal carcinomatosis, lymphatic, perineural or venous invasion, and 
histological properties including the level of invasion [5]. In Marzouk and Schofield´s review article 
[5], a number of potential molecular markers, such as microsatellite instability, BRAF mutation, 
KRAS mutation, PIK3CA mutations, and PTEN deletion, were evaluated for their potential 
prognostic value. Although they have been considered promising, the clinical value of these 
markers is still uncertain. More knowledge is already available about the role of 18q deletions and 
thymidylate synthase expression which have been associated with unfavorable prognosis and 
tumor recurrence. Even though many of these molecular markers have been used when choosing 
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the patients with metastatic disease to chemotherapy [5], new markers are still needed to 
distinguish different cancer types or to stratify the patients for personalized chemotherapy 
according to the cancer properties. 
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Conclusions  
Results of our study suggest that two isozymes, CA II and CA XII, significantly correlate with the 
patients´ survival rate. These proteins might have some value in the prognostic assessment of 
colorectal cancer patients when deciding which patients should undergo a more aggressive and 
demanding cancer treatment in order to curate cancer or postpone cancer progression.  
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Tables  
Table 1, Patient characteristics 
  Number of 
patients 
Percentage (%) 
Total  539 100 
    
Gender Male 294 54.5 
 Female 245 45.5 
    
Age < 65 year 231 42.9 
 ≥ 65 year 308 57.1 
    
Tumor location Right side of colon 157 29.1 
 Left side of colon 138 25.6 
 Rectum 244 45.3 
    
Stage Dukes A 82 15.2 
 Dukes B 191 35.4 
 Dukes C 136 25.2 
 Dukes D 130 24.1 
    
Differentiation High 19 3.5 
 Medium high 352 65.3 
 Medium low 141 26.2 
 Low 27 5.0 
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Table 2, Summary of CA staining statistics 
 Mean SD Median Mode 25 % 75 % 
CA II epithelium intensity  1.8 1.1 2 3 1 3 
       
CA II epithelium extent 2.2 1.1 3 3 2 3 
       
CA II endothelium 0.9 0.3 1 1 1 1 
       
CA VII epithelium intensity 1.4 1.0 1 1 1 2 
       
CA VII epithelium extent 2.0 1.2 3 3 1 3 
       
CA VII stromal intensity 2.8 0.5 3 3 3 3 
       
CA VII stromal extent 2.8 0.5 3 3 3 3 
       
CA IX epithelium intensity 1.7 1.2 2 3  3 
       
CA IX epithelium extent 1.6 1.2 2 3  3 
       
CA XII epithelium intensity 1.5 0.9 1 2 1 2 
       
CA XII epithelium extent 2.0 1.1 2 3 1 3 
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Table 3, COX regression analysis results of selected parameters. 
  
Hazard ratio 
CI 95 %  
lower 
CI 95 % 
upper 
p -value 
CA II epithelium intensity  1.19 1.04 1.37 0.0092 
Sex 1.20 0.92 1.58 0.1777 
Age over 65 years 1.78 1.35 2.35 0.0000 
Side of colon 1.17 0.86 1.58 0.3170 
     
CA II epithelium extent 0.88 0.73 1.05 0.1576 
Sex 1.25 0.95 1.64 0.1133 
Age over 65 years 0.64 0.32 1.25 0.1869 
Side of colon 1.14 0.84 1.55 0.3876 
     
Interaction between CA II 
epithelial intensity and age 
over 65 years 
1.59 1.22 2.09 0.0007 
     
CA XII epithelium intensity 1.18 1.01 1.38 0.0360 
Sex 1.23 0.94 1.60 0.1301 
Age over 65 years 1.67 1.27 2.19 0.0002 
Side of colon 1.09 0.81 1.47 0.5571 
     
 
Regression analyses are stratified by Dukes and differentiation status. 
Separate analyses were done for each CA staining. 
  
20 
 
Table 4, CA VII and Dukes class 
 
CA VII epithelial 
extent 
Dukes 
1A 
Count 
 
 
% 
 
2B 
Count 
 
 
% 
 
3C 
Count 
 
 
% 
 
4D 
Count 
 
 
% 
0  15 16.1 % 36 38.7 % 25 26.9 % 17 18.3 % 
         
1 14 19.7 % 31 43.7 % 14 19.7 % 12 16.9 % 
         
2 10 15.2 % 23 34.8 % 14 21.2 % 19 28.8 % 
         
3 28 11.4 % 85 34.6 % 67 27.2 % 66 26.8 % 
         
 
p= 0.013, linear by linear association test 
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Figure legends 
Figure 1. Distribution of carbonic anhydrases II, VII, IX, and XII in tissue sections. CA II (A,B,C), CA 
VII (D,E,F), CA IX (G,H,I), and CA XII (J,K,L) were immunohistochemically localized in specimens of 
normal pancreas (A,D,G,J), colon (B,E,H,K) and colorectal carcinoma (C,F,I,L). The normal pancreas 
and colon sections were used for control purposes. As expected, CA II is located to the pancreatic 
ducts and centroacinar cells, and in the normal colon the positive signal is strongest in the 
enterocytes of deep crypts. In the present example image of colorectal cancer, CA II antibody 
strongly labels the cancer cells. CA VII seems to stain strongly the stromal tissue. This 
phenomenon is seen in both the normal pancreas and colon as well as in colorectal cancer, 
whereas the cancer cells show only minimal if any staining. CA IX antibody weakly stains the ductal 
cells and some acinar cells of pancreatic tissue and also the basolateral cell membranes in basal 
parts of the colonic crypts. In colorectal cancer, CA IX shows strong staining in malignant cells, 
whereas the necrotic part remains negative. CA XII shows positive staining in the basolateral 
membranes of the pancreatic acinar cells and colonic enterocytes, and the malignant cells of colon 
carcinoma are also strongly positive for this isozyme. Original magnifications x 400.  
 
Figure 2. Kaplan-Meier figures of survival analysis of CA II, CA VII, CA IX and CA XII. Both CA II 
staining intensity (p=0.004) and extent (p=0.022) significantly correlated with the patient survival. 
A weak correlation was also found between the CA XII staining intensity and survival (p=0.020). 
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Figure 1. Distribution of carbonic anhydrases II, VII, IX, and XII in tissue sections  
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Figure 2. Kaplan-Meier figures of survival analysis of CA II, CA VII, CA IX and CA XII. 
